Oncostatin M decreases interleukin-1 β secretion by human synovial fibroblasts and attenuates an acute inflammatory reaction in vivo

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 6, 2012, Pages 1274-1285

  Dumas, Aline ^a   Lagarde, Stéphanie ^a   Laflamme, Cynthia ^a   Pouliot, Marc ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Cytokines chemokines; Inflammation; Murine dorsal air pouch; Neutrophils; Oncostatin M; Synovial fibroblasts

Indexed keywords

CCL2 PROTEIN, HUMAN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IL8 PROTEIN, HUMAN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKEMIA INHIBITORY FACTOR; LIF PROTEIN, HUMAN; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; ONCOSTATIN M; OSM PROTEIN, HUMAN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; CELL CULTURE; CYTOLOGY; DRUG EFFECT; FIBROBLAST; GENE EXPRESSION PROFILING; GENETICS; HUMAN; INFLAMMATION; MALE; METABOLISM; MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SECRETION (PROCESS); SIGNAL TRANSDUCTION; SYNOVIAL FLUID;

ANIMALS; CELLS, CULTURED; CHEMOKINE CCL2; FIBROBLASTS; GENE EXPRESSION PROFILING; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; LEUKEMIA INHIBITORY FACTOR; LIPOPOLYSACCHARIDES; MALE; MICE; ONCOSTATIN M; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 84861568461     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01412.x     Document Type: Article

References (72)

1. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol. 2003; 149: 39-52.
2. Zarling JM, Shoyab M, Marquardt H, et al. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci U S A. 1986; 83: 9739-43.
3. Kishimoto T, Akira S, Narazaki M, et al. Interleukin-6 family of cytokines and gp130. Blood. 1995; 86: 1243-54.
4. Heinrich PC, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003; 374: 1-20.
5. Mosley B, De Imus C, Friend D, et al. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem. 1996; 271: 32635-43.
6. Kuropatwinski KK, De Imus C, Gearing D, et al. Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6. J Biol Chem. 1997; 272: 15135-44.
7. Thoma B, Bird TA, Friend DJ, et al. Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. J Biol Chem. 1994; 269: 6215-22.
8. Gadient RA, Patterson PH. Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Stem Cells. 1999; 17: 127-37.
9. Modur V, Feldhaus MJ, Weyrich AS, et al. Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest. 1997; 100: 158-68.
10. Boniface K, Diveu C, Morel F, et al. Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol. 2007; 178: 4615-22.
11. Fritz DK, Kerr C, Fattouh R, et al. A mouse model of airway disease: oncostatin M-induced pulmonary eosinophilia, goblet cell hyperplasia, and airway hyperresponsiveness are STAT6 dependent, and interstitial pulmonary fibrosis is STAT6 independent. J Immunol. 2011; 186: 1107-18.
12. O'Hara KA, Kedda MA, Thompson PJ, et al. Oncostatin M: an interleukin-6-like cytokine relevant to airway remodelling and the pathogenesis of asthma. Clin Exp Allergy. 2003; 33: 1026-32.
13. Wallace PM, Macmaster JF, Rillema JR, et al. In vivo properties of oncostatin M. Ann N Y Acad Sci. 1995; 762: 42-54.
14. Hurst SM, McLoughlin RM, Monslow J, et al. Secretion of oncostatin M by infiltrating neutrophils: regulation of IL-6 and chemokine expression in human mesothelial cells. J Immunol. 2002; 169: 5244-51.
15. Richards CD, Langdon C, Botelho F, et al. Oncostatin M inhibits IL-1-induced expression of IL-8 and granulocyte-macrophage colony-stimulating factor by synovial and lung fibroblasts. J Immunol. 1996; 156: 343-9.
16. Brown TJ, Liu J, Brashem-Stein C, et al. Regulation of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor expression by oncostatin M. Blood. 1993; 82: 33-7.
17. Loy JK, Davidson TJ, Berry KK, et al. Oncostatin M: development of a pleiotropic cytokine. Toxicol Pathol. 1999; 27: 151-5.
18. Wallace PM, MacMaster JF, Rouleau KA, et al. Regulation of inflammatory responses by oncostatin M. J Immunol. 1999; 162: 5547-55.
19. Minehata K, Takeuchi M, Hirabayashi Y, et al. Oncostatin m maintains the hematopoietic microenvironment and retains hematopoietic progenitors in the bone marrow. Int J Hematol. 2006; 84: 319-27.
20. Esashi E, Ito H, Minehata K, et al. Oncostatin M deficiency leads to thymic hypoplasia, accumulation of apoptotic thymocytes and glomerulonephritis. Eur J Immunol. 2009; 39: 1664-70.
21. Grenier A, Dehoux M, Boutten A, et al. Oncostatin M production and regulation by human polymorphonuclear neutrophils. Blood. 1999; 93: 1413-21.
22. Okamoto H, Yamamura M, Morita Y, et al. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 1997; 40: 1096-105.
23. Cross A, Edwards SW, Bucknall RC, et al. Secretion of oncostatin M by neutrophils in rheumatoid arthritis. Arthritis Rheum. 2004; 50: 1430-6.
24. Pillinger MH, Abramson SB. The neutrophil in rheumatoid arthritis. Rheum Dis Clin North Am. 1995; 21: 691-714.
25. Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol. 2005; 115: 118-28.
26. Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev. 2008; 223: 252-70.
27. Lee DM, Kiener HP, Agarwal SK, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science. 2007; 315: 1006-10.
28. Buckley CD, Filer A, Haworth O, et al. Defining a role for fibroblasts in the persistence of chronic inflammatory joint disease. Ann Rheum Dis. 2004; 63: ii92-5.
29. Kim HJ, Krenn V, Steinhauser G, et al. Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol. 1999; 162: 3053-62.
30. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968; 97: 77-89.
31. Pouliot M, Fiset ME, Masse M, et al. Adenosine up-regulates cyclooxygenase-2 in human granulocytes: impact on the balance of eicosanoid generation. J Immunol. 2002; 169: 5279-86.
32. Cadieux JS, Leclerc P, St-Onge M, et al. Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal. J Cell Sci. 2005; 118: 1437-47.
33. McColl SR, St-Onge M, Dussault AA, et al. Immunomodulatory impact of the A2A adenosine receptor on the profile of chemokines produced by neutrophils. Faseb J. 2006; 20: 187-9.
34. St-Onge M, Flamand N, Biarc J, et al. Characterization of prostaglandin E2 generation through the cyclooxygenase (COX)-2 pathway in human neutrophils. Biochim Biophys Acta. 2007; 1771: 1235-45.
35. Dussault AA, Pouliot M. Rapid and simple comparison of messenger RNA levels using real-time PCR. Biol Proced Online. 2006; 8: 1-10.
36. Korzus E, Nagase H, Rydell R, et al. The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J Biol Chem. 1997; 272: 1188-96.
37. David M, Petricoin E, III, Benjamin C, et al. Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins. Science. 1995; 269: 1721-3.
38. Winston LA, Hunter T. JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. J Biol Chem. 1995; 270: 30837-40.
39. Edwards JC, Sedgwick AD, Willoughby DA. The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system. J Pathol. 1981; 134: 147-56.
40. Schiff MH. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis. 2000; 59: i103-8.
41. Saijo S, Asano M, Horai R, et al. Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum. 2002; 46: 533-44.
42. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002; 20: S1-13.
43. Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology. 2003; 42: ii11-6.
44. Pretzel D, Pohlers D, Weinert S, et al. In vitro model for the analysis of synovial fibroblast-mediated degradation of intact cartilage. Arthritis Res Ther. 2009; 11: R25.
45. Joosten LA, Helsen MM, Saxne T, et al. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol. 1999; 163: 5049-55.
46. Trebec-Reynolds DP, Voronov I, Heersche JN, et al. IL-1alpha and IL-1beta have different effects on formation and activity of large osteoclasts. J Cell Biochem. 2010; 109: 975-82.
47. Chen SY, Shiau AL, Shieh GS, et al. Amelioration of experimental arthritis by a telomerase-dependent conditionally replicating adenovirus that targets synovial fibroblasts. Arthritis Rheum. 2009; 60: 3290-302.
48. Ritchlin C. Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Res. 2000; 2: 356-60.
49. Brown TJ, Rowe JM, Liu JW, et al. Regulation of IL-6 expression by oncostatin M. J Immunol. 1991; 147: 2175-80.
50. Langdon C, Leith J, Smith F, et al. Oncostatin M stimulates monocyte chemoattractant protein-1-induced and interleukin-1-induced matrix metalloproteinase-1 production by human synovial fibroblasts in vitro. Arthritis Rheum. 1997; 40: 2139-46.
51. Van Wagoner NJ, Choi C, Repovic P, et al. Oncostatin M regulation of interleukin-6 expression in astrocytes: biphasic regulation involving the mitogen-activated protein kinases ERK1/2 and p38. J Neurochem. 2000; 75: 563-75.
52. Bernard C, Merval R, Lebret M, et al. Oncostatin M induces interleukin-6 and cyclooxygenase-2 expression in human vascular smooth muscle cells: synergy with interleukin-1beta. Circ Res. 1999; 85: 1124-31.
53. Repovic P, Mi K, Benveniste EN. Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: synergy with interleukin-1beta, tumour necrosis factor-alpha, and bacterial lipopolysaccharide. Glia. 2003; 42: 433-46.
54. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol. 1994; 55: 97-179.
55. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest. 1989; 84: 1045-9.
56. Deshmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009; 29: 313-26.
57. Shireman PK, Contreras-Shannon V, Ochoa O, et al. MCP-1 deficiency causes altered inflammation with impaired skeletal muscle regeneration. J Leukoc Biol. 2007; 81: 775-85.
58. Dessing MC, van der Sluijs KF, Florquin S, et al. Monocyte chemoattractant protein 1 contributes to an adequate immune response in influenza pneumonia. Clin Immunol. 2007; 125: 328-36.
59. Nakano Y, Kasahara T, Mukaida N, et al. Protection against lethal bacterial infection in mice by monocyte-chemotactic and -activating factor. Infect Immun. 1994; 62: 377-83.
60. Scholz W. Interleukin 6 in diseases: cause or cure?Immunopharmacol. 1996; 31: 131-50.
61. Tilg H, Trehu E, Atkins MB, et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumour necrosis factor receptor p55. Blood. 1994; 83: 113-8.
62. Wahl AF, Wallace PM. Oncostatin M in the anti-inflammatory response. Ann Rheum Dis. 2001; 60: iii75-80.
63. Liu J, Hadjokas N, Mosley B, et al. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. Cytokine. 1998; 10: 295-302.
64. Wang Y, Robledo O, Kinzie E, et al. Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor. J Biol Chem. 2000; 275: 25273-85.
65. Blanchard F, Wang Y, Kinzie E, et al. Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms. J Biol Chem. 2001; 276: 47038-45.
66. Hosokawa Y, Hosokawa I, Ozaki K, et al. Catechins inhibit CXCL10 production from oncostatin M-stimulated human gingival fibroblasts. J Nutr Biochem. 2010; 21: 659-64.
67. Ichihara M, Hara T, Kim H, et al. Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice. Blood. 1997; 90: 165-73.
68. Stahl N, Boulton TG, Farruggella T, et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science. 1994; 263: 92-5.
69. VanDeusen JB, Shah MH, Becknell B, et al. STAT-1-mediated repression of monocyte interleukin-10 gene expression in vivo. Eur J Immunol. 2006; 36: 623-30.
70. Ma Z, Qin H, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha. J Immunol. 2001; 167: 5150-9.
71. Ganster RW, Taylor BS, Shao L, et al. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B. Proc Natl Acad Sci U S A. 2001; 98: 8638-43.
72. Liu X, Ye L, Bai Y, et al. Activation of the JAK/STAT-1 signaling pathway by IFN-gamma can down-regulate functional expression of the MHC class I-related neonatal Fc receptor for IgG. J Immunol. 2008; 181: 449-63.